阿托伐他汀对糖尿病肾病患者炎症状态的影响被引量：11

Effects of atorvastatin on inflammation in patients with diabetic nephropathy

下载PDF

导出

摘要目的:观察阿托伐他汀对糖尿病肾病患者血清C反应蛋白(CRP)、单核细胞趋化蛋白-1(MCP-1)及尿白蛋白排泄率(UAER)的影响。方法:糖尿病肾病患者108例,随机均分为一般治疗组和阿托伐他汀治疗组。其中一般治疗组仅给予一般性治疗(包括控制血糖、血压等),阿托伐他汀治疗组给予一般治疗加阿托伐他汀40 mg/d,共观察12周。另取20名健康体检者作为对照组。所有研究对象分别于治疗前及治疗4周、8周、12周后各采静脉血1次,测定血清CRP、MCP-1和代谢指标空腹血糖、血脂(总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯),并采集24 h尿检测UAER。结果:阿托伐他汀治疗组血浆CRP、MCP-1及UAER水平在治疗前与一般治疗组患者差异均无统计学意义(P>0.05),在治疗后均明显低于一般治疗组(P<0.01),且随着治疗时间的延长,阿托伐他汀治疗组血浆CRP、MCP-1及UAER水平均有明显降低(P<0.01);血浆CRP、MCP-1与UAER均呈正相关关系(P<0.01)。结论:阿托伐他汀可能通过抑制炎症反应而保护糖尿病肾病患者的肾脏功能。 Objective：To observe the effect of atorvastatin on creactive protein（CRP）,monocyte chemoattractant protein-1（MCP-1）and urinary albumin excretion rate（UAER）in patients with diabetic nephropathy（DN）.Methods：One hundred and eight DN patients were randomly divided into treatment group（54 cases）and atorvastatin group（54 cases）.The treatment group were administered the routine therapy and the atorvastatin group received atorvastatin 40 mg daily.The therapies lasted for 12 weeks in both groups.Twenty healthy people acted as control.Serum CRP,MCP-1,glucose,lipids levels and UAER were compared between the two groups before treatment and 4,8,12 weeks after treatment.Results：Levels of plasma CRP,MCP-1 and UAER had no obvious difference between the two groups before treatment（P0.05）,but the above levels decreased significant in atorvastatin group after the therapy（P0.01）.Serum CRP,MCP-1 and UAER presented a positive correlation（P0.01）.Conclusions：Atorvastatin could effectively decrease the urinary protein excretion by restraining inflammation in DN patients.

作者闫永红张超徐俊蛟杨晓秋

机构地区上海市嘉定区南翔医院急诊科

出处《蚌埠医学院学报》 CAS 2010年第10期1018-1020,共3页 Journal of Bengbu Medical College

基金上海市嘉定区卫生局基金资助项目(KYXM2009-12-7)

关键词糖尿病肾病阿托伐他汀炎症 C反应蛋白单核细胞趋化蛋白-1 diabetic nephropathy atorvastatin inflammation creactive protein monocyte chemoattractant protein-1

分类号 R587.24 [医药卫生—内分泌]

引文网络
相关文献

参考文献9

1Navarro JF,Mora C,Macia M,et al.Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus[J].Am J Kidney Dis,2003,42(1):53-61.
2Banba N,Nakamura T,Matsumura M,et al.Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy[J].Kidney Int,2000,58(2):684-690.
3Mach F.Statins as immunomodulators[J].Transpl Immunol,2002,9(2/4):197-200.
4Sassy-Prigent C,Heudes D,Mandet C,et al.Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats[J].Diabetes,2000,49(3):466-475.
5Navarro JF,Mora C,Maca M,et al.Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus[J].Am J Kidney Dis,2003,42(1):53-61.
6Shanmugam N,Reddy MA,Guha M,et al.High Glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells[J].Diabetes,2003,52(5):1256-1264.
7Hensley K,Robinson KA,Gabbita SP,et al.Reactive oxygen species,cell signaling,and cell injury[J].Free Radic Biol Med,2000,28(10):1456-1462.
8Kitada M,Koya D,Sugimoto T,et al.Translocation of glomerular p47phox and p67phox by protein kinase C-activation is required for oxidative stress in diabetic nephropathy[J].Diabetes,2003,52(10):2603-2614.
9张敏芳,钱家麒,Tomino Yasuhiko.二十碳五烯酸对早期糖尿病肾病小鼠炎症和氧化应激状态的作用[J].中国中西医结合肾病杂志,2008,9(8):668-670. 被引量：3

二级参考文献10

1Baggio B, Musacchio E, Priante G. Polyunsaturated fatty acids and renal fibrosis: pathophysiologie link and potential clinical implications. J Nephrol, 2005,18 (4) : 362 - 367.
2James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr, 2000,71 (1 Suppl) : 343S - 348S.
3Caughey GE, Mantzioris E, Gibson RA, et al. The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n - 3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr, 1999,63(1) : 116 - 122.
4Viedt C,Orth SR. Monocyte chemoattractant protein-1 (MCP - 1 ) in the kidney:does it more than simply attract monocytes? Nephrol Dial Transplant,2002,17(12) :2043 - 2047.
5Hagiwara S,Makita Y,Gu L, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP - 1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant, 2006, 21 (3) :605- 615.
6Mori TA, Woodman R J, Burke V, et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated hypertensive type 2 diabees subjects. Free Radic Biol Med, 2003,35 (7) : 772 - 781.
7Jain S, Gaiha M, Bhattacharjee J, et al. Effects of low - dove omega- 3 fatty acids substitution in type 2 diabetes mellitus with special reference to oxidative stress - a prospective preliminary study. J Assoc Physicians India, 2002,50(8):1028 - 1033.
8Diep QN, Amiri F, Touyz RM, et al. PPARα activator effects on Ang Ⅱ- induced vascular oxidative stress and inflammation. Hypertension, 2002,40(6) :866 - 871.
9Sirtori CR, Crepaldi G, Manzato E, et al. One - year treatment with ethyl esters of n - 3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: Reduced triglyceridemia, total cholesterol and increased HDL - C without glycemic alterations. Atherosclerosis, 1998,137(2) :419 - 427.
10Storlien LH, Jenkins AB, Chisholm DJ, et al. Influence of dietary fat composition on development of insulin resistance in rats. Diabetes, 1991,40(2) :280 - 289.